ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
PremiumPress ReleasesESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
4M ago
Essa Pharma reports Q2 EPS (20c), consensus (19c)
Premium
The Fly
Essa Pharma reports Q2 EPS (20c), consensus (19c)
4M ago
Premium
Company Announcements
ESSA Pharma Shareholders Show Strong Support
7M ago
ESSA Pharma Reports Progress in Masofaniten Study
PremiumCompany AnnouncementsESSA Pharma Reports Progress in Masofaniten Study
8M ago
Essa Pharma: Masofaniten, enzalutamide continue to be well tolerated
Premium
The Fly
Essa Pharma: Masofaniten, enzalutamide continue to be well tolerated
8M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
8M ago
Essa Pharma presents Phase 1 clinical data of masofaniten in prostate cancer
PremiumThe FlyEssa Pharma presents Phase 1 clinical data of masofaniten in prostate cancer
11M ago
Essa Pharma presents updated Phase 1 Masofaniten clinical data
Premium
The Fly
Essa Pharma presents updated Phase 1 Masofaniten clinical data
11M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100